scholarly journals Use of drugs, alcohol and tobacco by people with schizophrenia: case–control study

2002 ◽  
Vol 181 (4) ◽  
pp. 321-325 ◽  
Author(s):  
Robin G. McCreadie

BackgroundSpecialised services should be developed to help people with schizophrenia and associated substance misuse. The extent of the problem therefore needs to be known.AimsTo determine the use of drugs, alcohol and tobacco by people with schizophrenia drawn from rural, suburban and urban settings, and to compare use by general population control subjects.MethodPeople with schizophrenia (n=316) and general population controls of similar gender distribution, age and postcode area of residence (n=250) were identified in rural, urban and suburban areas of Scotland. Use of drugs and alcohol was assessed by the Schedules for Clinical Assessment in Neuropsychiatry, and use of tobacco by a questionnaire.ResultsMore patients than controls reported problem use of drugs in the past year (22 (7%) v. 5 (2%)) and at some time before then (50 (20%) v. 15 (6%)) and problem use of alcohol in the past year (42 (17%) v. 25 (10%)) but not at sometime previously (99 (40%) v. 84 (34%)). More patients were current smokers (162 (65%) v. 99(40%)).ConclusionsProblem use of drugs and alcohol by people with schizophrenia is greater than in the general population, but absolute numbers are small. Tobacco use is the greatest problem.

Rheumatology ◽  
2020 ◽  
Author(s):  
Liselotte Tidblad ◽  
Helga Westerlind ◽  
Bénédicte Delcoigne ◽  
Johan Askling ◽  
Saedis Saevarsdottir

Abstract Objectives Comorbidities contribute to the morbidity and mortality in rheumatoid arthritis (RA), and are thus important to capture and treat early. In contrast to the well-studied comorbidity risks in established RA, less is known about the comorbidity pattern up until diagnosis of RA. We therefore compared if the occurrence of defined conditions, and the overall comorbidity burden at RA diagnosis, is different from that in the general population, and if it differs between seropositive and seronegative RA. Methods Using Swedish national clinical and demographic registers, we identified new-onset RA patients (n = 11 086), and matched (1:5) to general population controls (n = 54 813). Comorbidities prior to RA diagnosis were identified in the Patient and Prescribed Drug Registers, and compared using logistic regression. Results At diagnosis of RA, respiratory (OR = 1.58, 95% CI = 1.44–1.74), endocrine (OR = 1.39, 95% CI = 1.31–1.47), and certain neurological diseases (OR = 1.73, 95% CI = 1.59–1.89) were more common in RA vs controls, with a similar pattern in seropositive and seronegative RA. In contrast, psychiatric disorders (OR = 0.87, 95% CI = 0.82–0.92) and malignancies (OR = 0.88, 95% CI = 0.79–0.97) were less commonly diagnosed in RA vs controls. The comorbidity burden was slightly higher in RA patients compared with controls (p< 0.0001). Conclusion We found several differences in comorbidity prevalence between patients with new-onset seropositive and seronegative RA compared with matched controls from the general population. These findings are important both for our understanding of the evolvement of comorbidities in established RA and for early detection of these conditions.


2021 ◽  
Vol 15 (7) ◽  
pp. 2144-2146
Author(s):  
Sareh Alavirad ◽  
Ali Amiri

Background: Regarding increasing and concerning worldwide trends of doping and lack of definite information about contributing factors in this era, this study was performed to determine the frequency of social phobia in athletes with doping history in comparison with general population. Methods and materials: In this case-control study 30 subjects were enrolled including two groups of professional athletes with doping history and general population. In each group 15 subjects were present. All subjects were interviewed according to DSM-IV criteria. The social phobia was assessed by social phobia inventory (SPIN). Results: Ten subjects (including 7 men and 3 women) in athletes group and 6 subjects (including 4 men and 2 women) in normal population group had social phobia showing no significant difference between groups (P=0.143). The gender had no effect on having social phobia in none of the groups (P=1.000). Conclusions: Totally, according to the obtained results in this study, it may be concluded that there is no significant difference between presence of social phobia in athletes with doping history and general population. Keywords: Athletes, Doping, Social phobia


2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S536-S536
Author(s):  
V Peters ◽  
E Tigchelaar ◽  
M Campmans-Kuijpers ◽  
F Sheedfar ◽  
F Imhann ◽  
...  

BMJ ◽  
2001 ◽  
Vol 323 (7326) ◽  
pp. 1398-1401 ◽  
Author(s):  
F. Mulvany ◽  
E. O'Callaghan ◽  
N. Takei ◽  
M. Byrne ◽  
P. Fearon ◽  
...  

2008 ◽  
Vol 102 (1-3) ◽  
pp. 46
Author(s):  
Okochi Tomo ◽  
Masashi Ikeda ◽  
Taro Kishi ◽  
Kunihiro Kawashima Yoko Kinoshita ◽  
Tsuyoshi Kitajima ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document